[go: up one dir, main page]

BRPI0817860A2 - inibidores de histona deacetilase - Google Patents

inibidores de histona deacetilase

Info

Publication number
BRPI0817860A2
BRPI0817860A2 BRPI0817860A BRPI0817860A BRPI0817860A2 BR PI0817860 A2 BRPI0817860 A2 BR PI0817860A2 BR PI0817860 A BRPI0817860 A BR PI0817860A BR PI0817860 A BRPI0817860 A BR PI0817860A BR PI0817860 A2 BRPI0817860 A2 BR PI0817860A2
Authority
BR
Brazil
Prior art keywords
histone deacetylase
deacetylase inhibitors
inhibitors
histone
deacetylase
Prior art date
Application number
BRPI0817860A
Other languages
English (en)
Inventor
Karnambaram Anandhan
Prabhu Daivasigamani
Virendra Kachhadia
Abdul Raheem Keeri
Thanasekaran Ponpandian
Rajendran Praveen
Sridharan Rajagopal
Nirmala Rajagopalan
Original Assignee
Orchid Res Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Res Laboratories Limited filed Critical Orchid Res Laboratories Limited
Publication of BRPI0817860A2 publication Critical patent/BRPI0817860A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/44—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0817860A 2007-10-22 2008-10-21 inibidores de histona deacetilase BRPI0817860A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2384CH2007 2007-10-22
IN980CH2008 2008-04-21
PCT/IB2008/002799 WO2009053808A2 (en) 2007-10-22 2008-10-21 Histone deacetylase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0817860A2 true BRPI0817860A2 (pt) 2019-09-24

Family

ID=40580150

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817860A BRPI0817860A2 (pt) 2007-10-22 2008-10-21 inibidores de histona deacetilase

Country Status (14)

Country Link
US (1) US8450525B2 (pt)
EP (1) EP2209765A4 (pt)
JP (1) JP2011500783A (pt)
KR (1) KR20100074288A (pt)
CN (1) CN101896457A (pt)
AU (1) AU2008315651B2 (pt)
BR (1) BRPI0817860A2 (pt)
CA (1) CA2703231A1 (pt)
IL (1) IL205241A0 (pt)
MX (1) MX2010004402A (pt)
NZ (1) NZ584845A (pt)
RU (1) RU2453536C2 (pt)
WO (1) WO2009053808A2 (pt)
ZA (1) ZA201002841B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171690A1 (en) 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
EP2133334A1 (en) * 2008-06-09 2009-12-16 DAC S.r.l. Heterocyclic derivatives as HDAC inhibitors
EP2321264B1 (en) 2008-07-23 2016-05-04 President and Fellows of Harvard College Deacetylase inhibitors and uses thereof
WO2010028192A1 (en) 2008-09-03 2010-03-11 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
US20130040998A1 (en) * 2010-01-08 2013-02-14 Dana-Farber Cancer Institute, Inc. Fluorinated hdac inhibitors and uses thereof
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) * 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012117421A1 (en) * 2011-03-02 2012-09-07 Orchid Research Laboratories Ltd Histone deacetylase inhibitors
JP6240063B2 (ja) 2011-04-28 2017-11-29 ザ ブロード インスティテュート， インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2862259A1 (en) * 2011-12-29 2013-07-04 Pharmacyclics, Inc. Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8
CA2880117C (en) 2012-07-27 2021-04-06 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
ES2680224T3 (es) 2013-03-15 2018-09-05 Biomarin Pharmaceutical Inc. Inhibidores de HDAC
US10478431B2 (en) 2014-11-26 2019-11-19 The J. David Gladstone Institutes Methods for treating a cytomegalovirus infection
HK1250367A1 (zh) 2015-07-02 2018-12-14 Biomarin Pharmaceutical Inc. 组蛋白脱乙醯化酶抑制剂
IT201600074606A1 (it) * 2016-07-18 2018-01-18 Italfarmaco Spa New benzo-N-hydroxy amide compounds having antitumor activity
CN109496210A (zh) * 2016-07-26 2019-03-19 费森尤斯卡比肿瘤学有限公司 贝利司他的多晶型及其制备方法
CN106977425B (zh) * 2017-04-01 2019-07-19 清华大学深圳研究生院 具有dna甲基转移酶和组蛋白去乙酰化酶抑制活性的异羟肟酸衍生物及其制备方法与应用
JP2021510733A (ja) 2018-01-12 2021-04-30 ケーディーエーシー セラピューティクス，インコーポレーテッドＫｄａｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ
TWI798463B (zh) * 2018-07-11 2023-04-11 大陸商上海和譽生物醫藥科技有限公司 免疫抑制劑及其製備方法和在藥學上的應用
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
CN115403483B (zh) * 2021-07-02 2024-01-26 河南省儿童医院郑州儿童医院 含二苯乙烯或二苯甲酮骨架的ca-4衍生物、药物组合物及其制备方法和应用
CN113461602B (zh) * 2021-07-07 2022-06-28 北京华氏信华科生物科技有限公司 具有hdac抑制活性的苯胺类化合物、制备方法、组合物及应用
US20230285331A1 (en) * 2022-01-24 2023-09-14 University Of South Carolina Tyrosine and resveratrol derivatives as novel modulators of cellular serine-adp-ribosylation

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3202100A1 (de) * 1982-01-23 1983-08-04 Basf Ag, 6700 Ludwigshafen Substituierte benzoesaeure-4-hydroxyanilide, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
US4808597A (en) * 1983-07-05 1989-02-28 Pfizer Inc. Method for inhibiting the degradation of cartilage
LU85558A1 (fr) * 1984-09-28 1986-04-03 Oreal Nouveaux derives naphtaleniques a action retinoique,leurs procedes de preparation et compositions medicamenteuse et cosmetique les contenant
ATE190051T1 (de) * 1989-06-14 2000-03-15 Smithkline Beecham Corp Imidazoalkensäure
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
GB9110532D0 (en) * 1991-05-15 1991-07-03 Smithkline Beecham Corp Chemical compounds
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
TW419461B (en) * 1993-06-16 2001-01-21 Bristol Myers Squibb Co Alicyclic phospholipase A2 inhibitors
US5416089A (en) * 1993-06-24 1995-05-16 The Du Pont Merck Pharmaceutical Company Polycyclic and heterocyclic chromophores for bis-imide tumoricidals
US5489611A (en) * 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
BR9712144A (pt) * 1996-09-30 1999-08-31 Hoechst Marion Roussel Inc Novos antagonistas de nmda (d- aspartato de n-metila).
WO1998032741A1 (en) * 1997-01-29 1998-07-30 Zeneca Limited Inhibitors of farnesyl protein transferase
AR011126A1 (es) * 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano y compuestos intermediarios.
JPH10287634A (ja) * 1997-04-11 1998-10-27 Otsuka Pharmaceut Co Ltd ベンゼン誘導体
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
WO1999041235A1 (en) * 1998-02-10 1999-08-19 Astrazeneca Uk Limited Farnesyl transferase inhibitors
US6624197B1 (en) * 1998-05-08 2003-09-23 Calyx Therapeutics, Inc. Diphenylethylene compounds
KR20070053362A (ko) 1999-11-23 2007-05-23 메틸진, 인크. 히스톤 디아세틸라제의 억제제
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2423744C (en) * 2000-09-29 2012-04-03 Prolifix Limited Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
AU2002327627B2 (en) * 2001-09-14 2006-09-14 Methylgene Inc. Inhibitors of histone deacetylase
US7868204B2 (en) * 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
CN100448844C (zh) * 2002-10-17 2009-01-07 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
JP4716734B2 (ja) * 2003-01-06 2011-07-06 イーライ リリー アンド カンパニー グルコキナーゼ活性化物質としての置換されたアリールシクロプロピルアセトアミド
US7244751B2 (en) * 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
US20050038125A1 (en) * 2003-08-15 2005-02-17 Smit Hobbe Friso Method for the treatment of arthritis and pain
US7935724B2 (en) * 2003-10-09 2011-05-03 Merck Hdac Research, Llc Thiophene and benzothiophene hydroxamic acid derivatives
WO2005097747A1 (en) * 2004-04-05 2005-10-20 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
US7368476B2 (en) * 2004-04-07 2008-05-06 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
JP2008501771A (ja) 2004-06-10 2008-01-24 キャンサー・リサーチ・テクノロジー・リミテッド ヒストン脱アセチル化酵素阻害剤
JPWO2006004215A1 (ja) * 2004-07-07 2008-04-24 協友アグリ株式会社 ベンゾオキサゾール化合物
KR100686531B1 (ko) * 2004-08-31 2007-02-23 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 아릴아미노메틸프로페닐 벤즈하이드록시아마이드 유도체 및 그의 제조방법
JP2008545013A (ja) * 2005-06-30 2008-12-11 ウイスコンシン アラムニ リサーチ ファンデーション ４−［（ｅ）−２−（５，６，７，８−テトラヒドロ−５，５，８，８−テトラメチル−２−ナフタレニル）−１−プロペニル］安息香酸類似体及びその製造方法と使用
KR100696139B1 (ko) * 2005-11-01 2007-03-20 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 알킬카바모일나프탈렌일옥시 옥테노일 하이드록시아마이드 유도체 및그의 제조방법
EP1951658B1 (en) * 2005-11-17 2012-09-26 Eli Lilly & Company Glucagon receptor antagonists, preparation and therapeutic uses
MX2009001619A (es) * 2006-08-11 2009-02-23 Methylgene Inc Potenciacion de compuestos antimicoticos.
EP2913322A3 (en) 2006-11-03 2015-11-11 Korea Research Institute Of Chemical Technology Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same
JP2009051735A (ja) * 2007-08-23 2009-03-12 Kyoyu Agri Kk ベンゾオキサゾール誘導体
EP2282723A2 (en) * 2008-03-26 2011-02-16 University of Oxford Endoplasmic reticulum targeting liposomes

Also Published As

Publication number Publication date
MX2010004402A (es) 2010-10-15
JP2011500783A (ja) 2011-01-06
AU2008315651A1 (en) 2009-04-30
CA2703231A1 (en) 2009-04-30
EP2209765A4 (en) 2010-12-01
AU2008315651B2 (en) 2012-12-13
RU2453536C2 (ru) 2012-06-20
US8450525B2 (en) 2013-05-28
RU2010120682A (ru) 2011-11-27
EP2209765A2 (en) 2010-07-28
ZA201002841B (en) 2010-12-29
WO2009053808A2 (en) 2009-04-30
US20100291003A1 (en) 2010-11-18
IL205241A0 (en) 2010-12-30
CN101896457A (zh) 2010-11-24
NZ584845A (en) 2011-09-30
KR20100074288A (ko) 2010-07-01
WO2009053808A3 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
BRPI0817860A2 (pt) inibidores de histona deacetilase
DK2010168T3 (da) Histondeacetylase-inhibitore
EP2265590A4 (en) SELECTIVE HISTONDEACETYLASE HEMMER
EP2217588A4 (en) INHIBITORS OF HISTONE DEACETYLASE
BRPI0916713A2 (pt) compostos inibidores de histona desacetilase de cicloalquilideno e heterocicloalquilideno
ZA200906609B (en) Inhibitors of histone deacetylase
CY2017016I1 (el) Αναστολεις πρωτεασωματος
BRPI0719204A2 (pt) Inibidores de hdac
EP2134680A4 (en) Histone deacetylase INHIBITORS
IL188692A0 (en) Histone deacetylase inhibitors
EP1789381A4 (en) INHIBITORS OF HISTONE DEACETYLASE
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
BRPI0806898A2 (pt) Inibidores de mek
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
AU2008300827A8 (en) Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
BRPI0810365A2 (pt) Inibidores de mlc-1 de indol 7-substituído
EP1991247A4 (en) BIFUNCTIONAL HISTONDEACETYLASE INHIBITORS
EP1991226A4 (en) Histone deacetylase INHIBITORS
EP2451790A4 (en) INHIBITORS OF HISTONE DEACETYLASE
BRPI0909159A2 (pt) inibidores baseados em hidroxamato de desacetilases b
BRPI0821247A2 (pt) Inibidores de histona deacetilase
DK2066662T3 (da) Serinhydrolaseinhibitorer
EP2205563A4 (en) NEW HISTONDEACETYLASE INHIBITORS
FR2911341B1 (fr) Inhibiteur de corrosion

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.